Skip to main content
×
×
Home

High- v. low-dose quetiapine in schizophrenia: meta-analysis

  • Nitesh Painuly (a1)
Abstract
Aims and method

To study the difference between high- and low-dose quetiapine in acute treatment of schizophrenia. Data available from published double-blind fixed-dose trials were combined and analysed.

Results

There was no statistically significant difference between high- (750–800 mg/day) and low-dose (300–400 mg/day) quetiapine in terms of the response rate, change in positive symptoms score and the discontinuation rates either as a result of lack of response or adverse effects.

Clinical implications

Combined evidence from fixed-dose trials does not support the prevalent practice of targeting the higher dose of quetiapine for optimal treatment response in schizophrenia.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      High- v. low-dose quetiapine in schizophrenia: meta-analysis
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      High- v. low-dose quetiapine in schizophrenia: meta-analysis
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      High- v. low-dose quetiapine in schizophrenia: meta-analysis
      Available formats
      ×
Copyright
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Corresponding author
Nitesh Painuly (nitesh.painuly@gmail.com)
Footnotes
Hide All

Declaration of interest

None.

Footnotes
References
Hide All
1 Citrome, L, Jaffe, A, Levine, J, Lindenmayer, JP. Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies. J Clin Psychiatry 2005; 66: 1512–6.
2 Sparshatt, A, Jones, S, Taylor, D. Quetiapine: dose-response relationship in schizophrenia. CNS Drugs 2008; 22: 4968.
3 Arvanitis, LA, Miller, BG. Multiple fixed dose of ‘Seroquel’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997; 42: 233–46.
4 King, DJ, Link, CGG, Kowalcyk, B. A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia. Psychopharmacology 1998; 137: 139–46.
5 Barzega, G, Bogetto, F, Maina, G, Ravizza, L. Quetiapine in schizophrenic patients: a high- and low-dose double-blind comparison. Eur J Psychiatry 2000; 14: 221–32.
6 Emsley, RA, Raniwalla, J, Bailey, PJ, Jones, AM. A comparison of the effects of quetiapine (‘Seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. Int Clin Psychopharmacol 2000; 15: 121–31.
7 Roy Chengappa, KN, Parepally, H, Brar, JS, Mullen, J, Shilling, A, Goldstein, JM. A random-assignment, double-blind, clinical trial of once- vs twice-daily administration of quetiapine fumarate in patients with schizophrenia or schizoaffective disorder: a pilot study. Can J Psychiatry 2003; 48: 187–94.
8 Conley, RR, Kelly, DL, Nelson, MW, Richardson, CM, Feldman, S, Benham, R, et al. Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. Clin Neuropharmacol 2005; 28: 163–8.
9 Kahn, RS, Schulz, C, Palazov, VD, Reyes, EB, Brecher, M, Svensson, O, et al. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double blind, placebo-controlled study. J Clin Psychiatry 2007; 68: 832–42.
10 Centre for Reviews and Dissemination. Undertaking Systematic Reviews of Research on Effectiveness: CRD's Guidance for Those Carrying Out or Commissioning Reviews. Centre for Reviews and Dissemination (CRD), Report 4 (2nd edn). CRD, 2001 (http://www.york.ac.uk/inst/crd/report4.htm).
11 Buckley, PF. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials. Curr Med Res Opin 2004; 20: 1357–63.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Bulletin
  • ISSN: 1758-3209
  • EISSN: 1758-3217
  • URL: /core/journals/bjpsych-bulletin
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 3
Total number of PDF views: 12 *
Loading metrics...

Abstract views

Total abstract views: 170 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 22nd July 2018. This data will be updated every 24 hours.

High- v. low-dose quetiapine in schizophrenia: meta-analysis

  • Nitesh Painuly (a1)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *